Drugs / Ad26.RSV.preF-RSV preF Protein Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03982199 | Aug 2019 → Jun 2022 | respiratory syncytial virus infectious disease | Janssen Vaccines & Prevention B.V. | Terminated | Met primary Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.RSV.preF-RSV preF Protein Vaccine | “Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.” PMID 36791161 ↗ Feb 2023 |
| Modality | Vaccine | “Ad26.RSV.preF-RSV preF protein vaccine” PMID 36791161 ↗ Feb 2023 |
| Route | Intramuscular | “single intramuscular (IM) injection” NCT03982199 ↗ |